tetano
Editor, Senior Moderator
Clin Rev Allergy Immunol
. 2020 May 28.
doi: 10.1007/s12016-020-08797-3. Online ahead of print.
COVID-19 and Asthma: Reflection During the Pandemic
Shuang Liu[SUP] 1 2 [/SUP], Yuxiang Zhi[SUP] 3 [/SUP], Sun Ying[SUP] 4 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and abnormal, overactivated innate immunity and "cytokine storms" have been proposed as potential pathological mechanisms for rapid COVID-19 progression. Theoretically, asthmatic patients should have increased susceptibility and severity for SARS-CoV-2 infection due to a deficient antiviral immune response and the tendency for exacerbation elicited by common respiratory viruses. However, existing studies have not shown an expected prevalence of asthmatic individuals among COVID-19 patients. Certain aspects of type 2 immune response, including type 2 cytokines (IL-4, IL-13, etc.) and accumulation of eosinophils, might provide potential protective effects against COVID-19. Furthermore, conventional therapeutics for asthma, including inhaled corticosteroids, allergen immunotherapy (AIT), and anti-IgE monoclonal antibody, might also reduce the risks of asthmatics suffering infection of the virus through alleviating inflammation or enhancing antiviral defense. The interactions between COVID-19 and asthma deserve further attention and clarification.
Keywords: Allergic diseases; Asthma; COVID-19; SARS-CoV-2; Type 2 immune response.
. 2020 May 28.
doi: 10.1007/s12016-020-08797-3. Online ahead of print.
COVID-19 and Asthma: Reflection During the Pandemic
Shuang Liu[SUP] 1 2 [/SUP], Yuxiang Zhi[SUP] 3 [/SUP], Sun Ying[SUP] 4 [/SUP]
Affiliations
- PMID: 32468411
- DOI: 10.1007/s12016-020-08797-3
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and abnormal, overactivated innate immunity and "cytokine storms" have been proposed as potential pathological mechanisms for rapid COVID-19 progression. Theoretically, asthmatic patients should have increased susceptibility and severity for SARS-CoV-2 infection due to a deficient antiviral immune response and the tendency for exacerbation elicited by common respiratory viruses. However, existing studies have not shown an expected prevalence of asthmatic individuals among COVID-19 patients. Certain aspects of type 2 immune response, including type 2 cytokines (IL-4, IL-13, etc.) and accumulation of eosinophils, might provide potential protective effects against COVID-19. Furthermore, conventional therapeutics for asthma, including inhaled corticosteroids, allergen immunotherapy (AIT), and anti-IgE monoclonal antibody, might also reduce the risks of asthmatics suffering infection of the virus through alleviating inflammation or enhancing antiviral defense. The interactions between COVID-19 and asthma deserve further attention and clarification.
Keywords: Allergic diseases; Asthma; COVID-19; SARS-CoV-2; Type 2 immune response.